Business Case

Identified expected penetration and uptake of a DMD therapy in EU-4 + UK using LSC center-based assessment (CBA) methodology to inform 5-year commercial forecast and dependent business decisions at a mid-sized European pharmaceutical company  

Our client, a mid-sized multi-national pharmaceutical company was looking to launch their DMD therapy in EU-4 + UK markets and sought a robust methodology to understand penetration and uptake. LSC utilized its CBA methodology to assess potential adoption at a center level. The CBA methodology allows LSC and its clients to fully understand the impact of access constraints, physician preference and patient suitability while identifying center-level adoption challenges and pain points in the patient journey. Based on the results of the CBA, LSC was able to develop a 5-year commercial forecast and determine prioritized areas of intervention to promote a successful launch